emd 1201081
Nucleic acidexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00729053)
Timeline
Indications
Mechanism of action
- Toll-like receptor 9AGONIST
TLR9 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- emd 1201081
- emd 1201081
- imo-2055
- imo-2055
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01360827 | Phase 1 | Aug 1, 2010 | Merck KGaA, University of Toulouse |
| NCT01040832 | Phase 2 | Dec 1, 2009 | Merck Serono |
| NCT00719199 | Phase 1 | Jan 1, 2009 | Merck Serono |
| NCT00633529 | Phase 1 | Nov 1, 2007 | Merck Serono |
| NCT00729053 | Phase 2 | Jun 1, 2004 | Aceragen, Inc/ |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck Serono | For profit | 3 | 3 | 2 | 2007 |
| Aceragen, Inc/ | For profit | 1 | 1 | 1 | 2004 |
| Merck KGaA | For profit | 1 | 1 | 1 | 2010 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2010 |
4 organizations
Page 1 / 1